Mefloquine
- Generic Name
- Mefloquine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16F6N2O
- CAS Number
- 53230-10-7
- Unique Ingredient Identifier
- TML814419R
- Background
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in ...
- Indication
Mefloquine is indicated for the treatment of mild to moderate cases of malaria caused by Plasmodium falciparum and Plasmodium vivax. It is effective against chloroquine-resistant forms of Plasmodium falciparum. Mefloquine is also indicated for the prophylaxis of malaria caused by Plasmodium falciparum and Plasmodium vivax, including chloroquine-resistant for...
- Associated Conditions
- Malaria caused by Plasmodium falciparum, Malaria caused by plasmodium vivax
- Associated Therapies
- -
Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 5820
- Registration Number
- NCT00811421
- Locations
- 🇧🇯
Faculté des Sciences de la Santé (FSS), Université d'Abomey Calavi, Allada, Benin
🇰🇪Kenya Medical Research Institute (KEMRI)/ CDC, Kisumu, Kenya
🇬🇦Medical Rsearch Unit (MRU), Albert Schweitzer Hospital, Lambaréné, Gabon
Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2021-04-19
- Target Recruit Count
- 31
- Registration Number
- NCT00761020
- Locations
- 🇺🇸
Walter Reed Army Institute of Research, Silver Spring, Maryland, United States
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 37
- Registration Number
- NCT00746941
- Locations
- 🇪🇸
Research Site, Madrid, Spain
The Effect of Malaria on Disease Progression of HIV/AIDS
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 197
- Registration Number
- NCT00499876
- Locations
- 🇬ðŸ‡
Komfo Anokye Teaching Hospital, Kumasi, Ghana
Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Institute of Tropical Medicine, Belgium
- Target Recruit Count
- 300
- Registration Number
- NCT00373048
- Locations
- 🇿🇲
Tropical Disease Research Center, Ndola, Cupperbelt, Zambia
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 397
- Registration Number
- NCT00367653
- Locations
- 🇿🇲
Pfizer Investigational Site, Ndola, Zambia
Kilimanjaro IPTi Drug Options Trial
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 2419
- Registration Number
- NCT00158574
- Locations
- 🇹🇿
Ministry of Health, Korogwe and Same District MCH clinics, Tanga, Tanga and Kilimanjaro, Tanzania
Antimalarial Drug Resistance in Mali
- Conditions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2006-08-16
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1011
- Registration Number
- NCT00127998
- Locations
- 🇲🇱
Koro Health Center, Koro, Mali
🇲🇱Faladje Missionary Dispensary, Faladje, Mali
🇲🇱Pongono Community Health Center, Pongono, Mali
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
- Conditions
- First Posted Date
- 2004-05-14
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 238
- Registration Number
- NCT00082576
- Locations
Pfizer Investigational Site
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.